Sin Hang Lee, MD, F.R.C.P. (C) Pathologist

Dr. Sin Lee is a pathologist who has been practicing for more than 40 years: as an attending Pathologist at Yale-affiliated teaching hospitals from 1973 to 2003. He was the Director of the Molecular Diagnostic Section at Milford Hospital Laboratory from 2004 to 2015. Since 2015, he is the Director of the Milford Molecular Diagnostics Laboratory.

Dr. Lee was born in Hong Kong, and received his medical degree from Tongji-Wuhan Medical University in China. He is a naturalized U.S. citizen, and a licensed medical doctor in in DC, New York, and Connecticut, in Canada. He is a board certified pathologist by the American Board of Pathology, and is a Certificated Specialist and is a fellow of the Royal College of Physicians and Surgeons of Canada.  Dr. Lee is a qualified medical practitioner registered at the General Medical Council in London. His expertise includes General pathology, surgical pathology, clinical microbiology and molecular diagnostics by PCR/direct DNA sequencing.

Dr. Lee developed two accurate DNA sequencing tests to improve treatment outcomes. The first test detects Lyme disease at an early stage, before the disease becomes chronic, thereby greatly improving treatment outcomes. The second is a DNA test to accurately detect HPV in women’s cervical cells for the diagnosis of persistent HPV infection, a risk for developing cervical cancer, thereby reducing unnecessary colposcopic biopsies which are performed too often.  Dr. Lee has conducted HPV DNA research involving the vaccine Gardasil, at the request of mothers whose daughters developed severe adverse reactions after HPV vaccination.

Dr. Lee’s publications include:

  • Single Core Genome Sequencing for Detection of both Borrelia burgdorferi Sensu Lato and Relapsing Fever Borrelia Species. International Journal of Environmental Research Public Health (2019)
  • Metagenomic 16S rRNA gene sequencing survey of Borrelia species in Irish samples of Ixodes ricinus ticks. PLoS One (2019)
  • Lyme disease caused by Borrelia burgdorferi with two homeologous 16S rRNA genes: a case report. International Medical Case Reports Journal (2016)
  • From Human Papillomavirus (HPV) Detection to Cervical Cancer Prevention in Clinical Practice. Cancers (Basel) (2014)
  • Detection of borreliae in archived sera from patients with clinically suspect Lyme disease. International Journal of Molecular Science (2014)
  • Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples. International Journal of Molecular Sciences (2016)
  • Melting profiles may affect detection of residual HPV L1 gene DNA fragments in Gardasil®. Current Medical Chemistry (2014)
  • Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil. Journal Inorganic Biochemistry (2012)

In an unprecedented anti-trust lawsuit, filed suit in federal court in October 2017, Dr. Lee accused the Centers for Disease Control and Prevention (CDC) of suppressing the use of the more accurate DNA Lyme detection test, and continues to endorse a less accurate serology test. His lawyer uncovered evidence of financial conflicts of interest; several CDC officials receive royalties for each of the faulty Lyme disease tests administered, and they will continue to receive money as long as these faulty tests are being used.

Dr. Lee laments the undue influence that industry has exerted on the practice of medicine: “It is unfortunate that the medical profession has become part of the healthcare industry and physicians are now classified as service providers.”